Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Regulatory Approval Market Competition Phase II Trials Eli Lilly Patient Outcomes Obesity Treatments Obesity Treatment FDA Regulations Metabolic Diseases Market Risks Efruxifermin Pharmacokinetics Efficacy Orforglipron Injectable Drugs Late-Stage Testing Influenza Treatment Drug Pipeline Preclinical Research Food Allergy Treatments GLP-1 Drugs Pipeline Management Patient Safety Efficacy Studies Treatment Options RNA Therapeutics Lung Cancer Treatment AGAMREE

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

GSK moves to fortify its immunology pipeline with a mid‑stage anti‑IgE drug that could shift food‑allergy care.

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Novel Non-Opioid Analgesic ADRIANA Advances to U.S. Phase II Trials

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion